We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » KNL PHARMA, ChiRhoClin DRAW WARNINGS FROM FDA
KNL PHARMA, ChiRhoClin DRAW WARNINGS FROM FDA
May 14, 2004
A pair of drugmakers received warning letters from the FDA recently — one for false and misleading claims for an herbal cancer treatment, the other for noncompliance with the postmarketing adverse drug experience (PADE) reporting requirements.